Beyond the Primary Endpoint: High-Dose Vilobelimab Demonstrates Clinical Utility in Reducing Draining Tunnels in Hidradenitis Suppurativa
Posted inAllergy & Immunology Dermatology news

Beyond the Primary Endpoint: High-Dose Vilobelimab Demonstrates Clinical Utility in Reducing Draining Tunnels in Hidradenitis Suppurativa

The SHINE trial, despite missing its primary endpoint due to a high placebo response, suggests that high-dose vilobelimab significantly reduces draining tunnels in moderate-to-severe hidradenitis suppurativa, offering a potential new therapeutic avenue for structural skin damage.
Baricitinib Demonstrates Superior Efficacy Over Azathioprine in Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Randomized Head-to-Head Trial
Posted inAllergy & Immunology Dermatology news

Baricitinib Demonstrates Superior Efficacy Over Azathioprine in Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Randomized Head-to-Head Trial

A randomized trial (NCT05969730) shows that baricitinib plus topical corticosteroids significantly outperformed azathioprine in achieving EASI 75 at 12 weeks (65% vs. 15%) in patients with moderate-to-severe atopic dermatitis, with both treatments showing favorable safety profiles.
Mapping Multimorbidity in Severe Asthma: Defining Replicable Phenotypes to Optimize Personalized Care
Posted inAllergy & Immunology Clinical Updates news Respiratory

Mapping Multimorbidity in Severe Asthma: Defining Replicable Phenotypes to Optimize Personalized Care

This review analyzes findings from the pan-European SHARP registry study, identifying distinct multimorbidity phenotypes in severe asthma. It highlights the impact of steroid-associated and sinonasal clusters on clinical outcomes, advocating for a holistic approach to complex patient management.
Tezepelumab Enables Complete Oral Corticosteroid Discontinuation in 50% of Patients with Severe, Uncontrolled Asthma: Results from the WAYFINDER Phase 3b Trial
Posted inAllergy & Immunology news Respiratory

Tezepelumab Enables Complete Oral Corticosteroid Discontinuation in 50% of Patients with Severe, Uncontrolled Asthma: Results from the WAYFINDER Phase 3b Trial

The WAYFINDER study reveals that tezepelumab significantly reduces OCS dependence in severe asthma, with over half of patients achieving complete discontinuation by week 52 while maintaining asthma control, regardless of baseline inflammatory biomarkers.
Redefining Reliever Therapy: Budesonide-Formoterol Outperforms SABA in Controlling Airway Inflammation Among Patients on Maintenance Corticosteroids
Posted inAllergy & Immunology news Respiratory

Redefining Reliever Therapy: Budesonide-Formoterol Outperforms SABA in Controlling Airway Inflammation Among Patients on Maintenance Corticosteroids

The INFORM ASTHMA trial demonstrates that budesonide-formoterol as a reliever significantly reduces Type 2 airway inflammation (FeNO) compared to terbutaline in adults already using maintenance inhaled corticosteroids, establishing a new evidence base for anti-inflammatory reliever strategies in moderate asthma.
Stratifying Risk in Cow’s Milk Allergy: BAT Emerges as the Superior Biomarker for Severity and Threshold
Posted inAllergy & Immunology news Pediatrics

Stratifying Risk in Cow’s Milk Allergy: BAT Emerges as the Superior Biomarker for Severity and Threshold

The BAT2 study reveals that the Basophil Activation Test (BAT) is the only biomarker capable of accurately predicting reaction severity to baked milk and the sensitivity threshold for fresh milk, offering a transformative tool for clinical risk assessment and personalized management of cow's milk allergy.
Posted inAllergy & Immunology Hematology-Oncology news

Precision Gene Correction via Prime Editing Restores NADPH Oxidase Activity in Patients with p47phox-Deficient Chronic Granulomatous Disease

A Phase 1/2 clinical trial demonstrates that PM359, an autologous prime-edited CD34+ cell therapy, successfully corrects the delGT mutation in NCF1, restoring essential microbicidal function in patients with p47-CGD without the off-target risks associated with traditional CRISPR-Cas9.